This publication was supported by Grant Number 1UL1RR033183 from the National Center for Research Resources (NCRR) of the National Institutes of Health (NIH) to the University of Minnesota Clinical and Translational Science Institute (CTSI). Its contents are soley the responsibility of the authors and do not necessarily represent the official views of the CTSI or the NIH. The University of Minnesota CTSI is part of a national Clinical and Translational Science Award (CTSA) consortium created to accelerate laboratory discoveries into treatments for patients.

Read the full text

About

PDF

Tools

Share a link

Email
Wechat
Bluesky

Abstract

Background

Head and neck squamous cell carcinoma (HNSCC) is associated with tobacco use. Still, most smokers do not develop HNSCC. The mechanisms of varying susceptibility to HNSCC are poorly studied to date. Tobacco metabolite research provides insight regarding the innate metabolism and excretion of carcinogens.

Methods

Smokers with HNSCC (cases) were compared with smokers without HNSCC (controls) in a matched cohort. The tobacco metabolites studied were: 1-hydroxypyrene (1-HOP), N′-nitrosonornicotine (NNN), and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL).

Results

In 33 subjects, mean 1-HOP was 1.82 pmol/mg creatinine versus 1.08 pmol/mg creatinine (p = .004) and mean NNN was 0.10 pmol/mg creatinine versus 0.04 pmol/mg creatinine (p = .01) in cases and controls, respectively. NNAL did not differ between groups.

Conclusions

Smokers with HNSCC have elevated urinary levels of 1-HOP and total NNN compared with matched controls, suggesting an increased effective exposure to these carcinogens. Tobacco constituent metabolites may be useful in understanding tobacco-related carcinogenesis in HNSCC. © 2012 Wiley Periodicals, Inc. Head Neck, 2013

REFERENCES

1 Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr, Doll R. Mortality from smoking worldwide. Br Med Bull 1996; 52: 12–21.
10.1093/oxfordjournals.bmb.a011519
CAS PubMed Web of Science® Google Scholar
2 World Health Organization. Tobacco or health: a global status report. Geneva: World Health Organization; 1997.
Google Scholar
3 Schlecht NF, Franco EL, Pintos J, Kowalski LP. Effect of smoking cessation and tobacco type on the risk of cancers in the upper aerodigestive tract in Brazil. Epidemiology 1999; 10: 412–418.
10.1097/00001648-199907000-00012
CAS PubMed Web of Science® Google Scholar
4 Day GL, Blot WJ, Shore RE, et al. Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol. J Natl Cancer Inst 1994; 86: 131–137.
10.1093/jnci/86.2.131
CAS PubMed Web of Science® Google Scholar
5 Sturgis EM, Wei Q, Spitz MR. Descriptive epidemiology and risk factors for head and neck cancer. Semin Oncol 2004; 31: 726–733.
10.1053/j.seminoncol.2004.09.013
PubMed Web of Science® Google Scholar
6 Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5–26.
10.3322/canjclin.53.1.5
CAS PubMed Web of Science® Google Scholar
7 Centers for Disease Control and Prevention (CDC). Tobacco use among adults—United States, 2005. MMWR Morb Mortal Wkly Rep 2006; 55: 1145–1148.
PubMed Google Scholar
8 Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults and trends in smoking cessation—United States, 2008. MMWR Morb Mortal Wkly Rep 2009; 58: 1227–1232.
PubMed Google Scholar
9 Duray A, Demoulin S, Hubert P, Delvenne P, Saussez S. Immune suppression in head and neck cancers: a review. Clin Dev Immunol 2010; 2010: 701657.
10.1155/2010/701657
CAS PubMed Web of Science® Google Scholar
10 IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum 2004; 83: 1–1438.
PubMed Google Scholar
11 Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 1998; 11: 559–603.
10.1021/tx980005y
CAS PubMed Web of Science® Google Scholar
12 Yuan JM, Koh WP, Murphy SE, et al. Urinary levels of tobacco-specific nitrosamine metabolites in relation to lung cancer development in two prospective cohorts of cigarette smokers. Cancer Res 2009; 69: 2990–2995.
10.1158/0008-5472.CAN-08-4330
CAS PubMed Web of Science® Google Scholar
13 Carmella SG, Le Ka KA, Upadhyaya P, Hecht SS. Analysis of N- and O-glucuronides of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine. Chem Res Toxicol 2002; 15: 545–550.
10.1021/tx015584c
CAS PubMed Web of Science® Google Scholar
14 Carmella SG, Han S, Fristad A, Yang Y, Hecht SS. Analysis of total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine. Cancer Epidemiol Biomarkers Prev 2003; 12( 11 Pt 1): 1257–1261.
CAS PubMed Web of Science® Google Scholar
15 Hecht SS. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 2002; 23: 907–922.
10.1093/carcin/23.6.907
CAS PubMed Web of Science® Google Scholar
16 IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures. IARC Monogr Eval Carcinog Risks Hum 2010; 92: 1–853.
PubMed Google Scholar
17 Carmella SG, Chen M, Han S, et al. Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers. Chem Res Toxicol 2009; 22: 734–741.
10.1021/tx800479s
CAS PubMed Web of Science® Google Scholar
18 Hecht SS, Yuan JM, Hatsukami D. Applying tobacco carcinogen and toxicant biomarkers in product regulation and cancer prevention. Chem Res Toxicol 2010; 23: 1001–1008.
10.1021/tx100056m
CAS PubMed Web of Science® Google Scholar
19 Stepanov I, Hecht SS. Tobacco-specific nitrosamines and their pyridine-N-glucuronides in the urine of smokers and smokeless tobacco users. Cancer Epidemiol Biomarkers Prev 2005; 14: 885–891.
10.1158/1055-9965.EPI-04-0753
CAS PubMed Web of Science® Google Scholar
20 Du X, Squier CA, Kremer MJ, Wertz PW. Penetration of N-nitrosonornicotine (NNN) across oral mucosa in the presence of ethanol and nicotine. J Oral Pathol Med 2000; 29: 80–85.
10.1034/j.1600-0714.2000.290205.x
CAS PubMed Google Scholar
21 Carmella SG, Akerkar SA, Richie JP Jr, Hecht SS. Intraindividual and interindividual differences in metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers' urine. Cancer Epidemiol Biomarkers Prev 1995; 4: 635–642.
CAS PubMed Web of Science® Google Scholar
22 Carmella SG, Le KA, Hecht SS. Improved method for determination of 1-hydroxypyrene in human urine. Cancer Epidemiol Biomarkers Prev 2004; 13: 1261–1264.
10.1158/1055-9965.1261.13.7
CAS PubMed Web of Science® Google Scholar
23 Hochalter JB, Zhong Y, Han S, Carmella SG, Hecht SS. Quantitation of a minor enantiomer of phenanthrene tetraol in human urine: correlations with levels of overall phenanthrene tetraol, benzo[a]pyrene tetraol, and 1-hydroxypyrene. Chem Res Toxicol 2011; 24: 262–268.
10.1021/tx100391z
CAS PubMed Web of Science® Google Scholar
24 Stepanov I, Carmella SG, Briggs A, et al. Presence of the carcinogen N′-nitrosonornicotine in the urine of some users of oral nicotine replacement therapy products. Cancer Res 2009; 69: 8236–8240.
10.1158/0008-5472.CAN-09-1084
CAS PubMed Web of Science® Google Scholar
25 Porubin D, Hecht SS, Li ZZ, Gonta M, Stepanov I. Endogenous formation of N′-nitrosonornicotine in F344 rats in the presence of some antioxidants and grape seed extract. J Agric Food Chem 2007; 55: 7199–7204.
10.1021/jf0712191
CAS PubMed Web of Science® Google Scholar
26 Stepanov I, Hecht SS. Detection and quantitation of N′-nitrosonornicotine in human toenails by liquid chromatography-electrospray ionization-tandem mass spectrometry. Cancer Epidemiol Biomarkers Prev 2008; 17: 945–948.
10.1158/1055-9965.EPI-07-2711
CAS PubMed Web of Science® Google Scholar
27 Alexandrie AK, Warholm M, Carstensen U, et al. CYP1A1 and GSTM1 polymorphisms affect urinary 1-hydroxypyrene levels after PAH exposure. Carcinogenesis 2000; 21: 669–676.
10.1093/carcin/21.4.669
CAS PubMed Web of Science® Google Scholar
28 Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003; 3: 733–744.
10.1038/nrc1190
CAS PubMed Web of Science® Google Scholar
29 Hoffmann D, Hecht SS. In: CS Cooper, PL Grover, editors. Handbook of Experimental Pharmacology. Heidelberg: Springer–Verlag; 1990. pp. 63–102.
Web of Science® Google Scholar
30 Yuan JM, Knezevich AD, Wang R, Gao YT, Hecht SS, Stepanov I. Urinary levels of the tobacco-specific carcinogen N′-nitrosonornicotine and its glucuronide are strongly associated with esophageal cancer risk in smokers. Carcinogenesis 2011; 32: 1366–1371.
10.1093/carcin/bgr125
CAS PubMed Web of Science® Google Scholar
31 Church TR, Anderson KE, Caporaso NE, et al. A prospectively measured serum biomarker for a tobacco-specific carcinogen and lung cancer in smokers. Cancer Epidemiol Biomarkers Prev 2009; 18: 260–266.
10.1158/1055-9965.EPI-08-0718
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume35, Issue8

August 2013

Pages 1096-1100

Elevated levels of 1-hydroxypyrene and N′-nitrosonornicotine in smokers with head and neck cancer: A matched control study^†

Abstract

Background

Methods

Results

Conclusions

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Elevated levels of 1-hydroxypyrene and N′-nitrosonornicotine in smokers with head and neck cancer: A matched control study†

Abstract

Background

Methods

Results

Conclusions

REFERENCES

Citing Literature

References

Related

Information

Elevated levels of 1-hydroxypyrene and N′-nitrosonornicotine in smokers with head and neck cancer: A matched control study^†